Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Clinical practice effect of rosiglitazone discontinuation on glycemic control.

Fanning EL, Weissman PN, Menditto LA.

Endocr Pract. 2009 Apr;15(3):270-2. No abstract available.

PMID:
19364698
2.

Effect of short-term rosiglitazone therapy in peritoneal dialysis patients.

van Hooland S, Boey O, Van der Niepen P, Van den Branden C, Verbeelen D.

Perit Dial Int. 2009 Jan-Feb;29(1):108-11. No abstract available.

PMID:
19164260
3.

Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes.

Tran MT, Navar MD, Davidson MB.

Diabetes Care. 2006 Jun;29(6):1395-6. No abstract available.

PMID:
16732030
4.

Editorial: What have we lost in the wake of the rosiglitazone controversy?

Zarich SW, Nesto RW.

Endocr Pract. 2009 Apr;15(3):273-4. No abstract available.

PMID:
19364699
5.

A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study.

Halimi S, Aubert JP, Fontbonne A, Guillausseau PJ, Nachit F, Bouée S, Detournay B.

Diabetes Metab. 2012 Oct;38(4):343-51. doi: 10.1016/j.diabet.2012.03.002. Epub 2012 Apr 18.

PMID:
22521038
6.

Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.

Hollander P, Yu D, Chou HS.

Arch Intern Med. 2007 Jun 25;167(12):1284-90.

PMID:
17592102
7.

Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA).

Karamanos B, Thanopoulou A, Drossinos V, Charalampidou E, Sourmeli S, Archimandritis A; Hellenic ECLA Study Group.

Curr Med Res Opin. 2011 Feb;27(2):303-13. doi: 10.1185/03007995.2010.542081. Epub 2010 Dec 9.

PMID:
21142615
8.

Pioglitazone is a valid alternative to rosiglitazone.

Derosa G.

Am J Cardiovasc Drugs. 2011 Dec 1;11(6):357-62. doi: 10.2165/11595990-000000000-00000.

PMID:
21950735
9.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
10.

Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.

Varghese A, Yee MS, Chan CF, Crowe LA, Keenan NG, Johnston DG, Pennell DJ.

J Cardiovasc Magn Reson. 2009 Jul 27;11:24. doi: 10.1186/1532-429X-11-24.

11.

[Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].

[No authors listed]

MMW Fortschr Med. 2003 Dec 11;145(50):54. German. No abstract available.

PMID:
14963975
12.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
13.

Withdrawal of pioglitazone in patients with type 2 diabetes mellitus.

Iwase M, Asano T, Sasaki N, Yoshizumi H, Hiramatsu S, Sakai Y, Ogo A, Iida M.

J Clin Pharm Ther. 2010 Aug;35(4):401-8. doi: 10.1111/j.1365-2710.2009.01109.x.

PMID:
20831543
14.
15.

The new rosiglitazone story: its place today in type 2 diabetes management.

Ambery P, Pandya B.

Prim Care Diabetes. 2009 Feb;3(1):57-9. doi: 10.1016/j.pcd.2009.01.002. Epub 2009 Mar 9.

PMID:
19269912
16.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
17.
18.

Rosiglitazone/glimepiride (Avandaryl) for diabetes.

[No authors listed]

Med Lett Drugs Ther. 2006 Mar 13;48(1230):22-4. No abstract available.

PMID:
16538189
19.
20.

[World news in age-related diabetes: blood sugar lowering can improve prognosis].

Einecke D.

MMW Fortschr Med. 2005 Sep 22;147(38):1. German. No abstract available.

PMID:
16218218

Supplemental Content

Support Center